MG1111

BIOLOGICAL2 trials

Sponsors

Green Cross Corporation, GC Biopharma Corp

Conditions

Varicella (Chicken Pox)Varicella Zoster Virus Infection

Phase 1

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

CompletedNCT02367638

Green Cross CorporationVaricella (Chicken Pox)

Start: 2015-03-31Target: 39Updated: 2017-04-27

Unknown Phase

An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

GC Biopharma CorpVaricella Zoster Virus Infection

Start: 2023-02-28End: 2023-06-30Target: 250Updated: 2022-12-23